The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA grants Orphan Drug Designation Status for tasquinimod to treat MM
On 12th April 2017, tasquinimod from Active Biotech AB (Nasdaq Stockholm: ACTI) was granted Orphan Drug Designation status by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM)1.
Tasquinimod is a small molecule (second-generation quinoline-3-carboxamide variant) immunomodulatory drug that targets the tumor microenvironment by controlling metastatic and angiogenic function of myeloid derived suppressor cells (MDSCs). Specifically, it binds to the pro-inflammatory protein S100A9 (also known as migration inhibitory factor-related protein 14, MRP14), blocking its interaction with receptors TLR4, RAGE, and CD1472.
Previous development of tasquinimod focused on prostate cancer, with promising outcomes in phase 2 and 3 trials. Recently, pre-clinical studies using MM models have shown promising antitumor effects, including a significant reduction in angiogenesis in the bone marrow.
References